Scales NPAT down 73% to $5.2m while operating cash flow jumped 44%

What changed

Revenue fell 8.7% to $565.4m and reported EBITDA fell 21.7% to $53.7m (underlying EBITDA $67.5m, down 13%). PBT dropped 34.7% to $29.8m, while NPAT attributable to equity holders collapsed 73.0% to $5.2m. Segment mix shifted against Logistics, whose share of segment revenue fell 2.9pp to 15.3%, while Global Proteins gained 2.0pp to 49.4% and Horticulture was broadly steady.

Despite the earnings decline, operating cash flow rose 44.2% to $64.7m and cash rose to $77.6m. However, gross borrowings climbed 59.7% to $65.6m, so the net cash cushion halved to $12.0m from $24.7m. The announced interim dividend rose to 6.0 cents from 3.5 cents.

What matters

• PBT/NPAT gap is structural, not tax. The effective tax rate was almost unchanged (17.2% vs 16.2%), so the divergence between PBT down 35% and NPAT down 73% is not tax-driven. Profit from continuing operations was $5.2m against $38.2m prior; the extraction discloses no discontinued operation, so the $19–20m gap between implied after-tax profit and attributable NPAT appears to sit in non-controlling interests or a similar below-the-line allocation. This is the single most important item the release does not fully bridge for a reader.
• Cash generation diverged sharply from earnings. OCF/EBITDA rose to 120.5% from 65.5%, driven by inventory down 30.7% to $29.5m (days from 25.1 to 19.1) and receivables down 29.3% to $25.6m (days from 21.3 to 16.5). Pre-lease FCF rose to $47.9m from $30.3m. That is a working-capital release following the FY22 inventory build, not a recurring uplift.
• Leverage direction weakened even as cash rose. Gross borrowings up $24.5m while equity eased 1.8% to $384.9m. Underlying ROE fell to 1.4% from 5.0%. The balance sheet is still in net cash, but the trajectory has reversed.

Expectations

No FY24 guidance, forward-work backlog or quantified target was disclosed in the supplied materials, so this release cannot be judged against a company-set bar. The shape context is unfavourable: HY23 delivered 54.7% of full-year revenue, 56.8% of EBITDA and 74.4% of NPAT, implying a second half that was materially softer on margin and profit. Implied H2 EBITDA was $23.2m against $30.5m in H1, and implied H2 NPAT was only $1.3m. The release attributes part of the pressure to Cyclone Gabrielle volumes, but does not quantify the impact.

Quality of result

Earnings quality looks weaker than headline cash suggests. The operating cash lift is heavily working-capital assisted: combined trade receivables and inventory fell by $23.7m, which alone accounts for most of the $19.8m OCF uplift. EBITDA-to-OCF conversion above 120% is unlikely to repeat without a further destocking leg.

The dividend raise to 6.0 cents looks well covered by pre-lease FCF (payout ratio 17.7%) but sits at 162% of attributable NPAT, which is only sustainable if the PBT-to-NPAT gap narrows or underlying earnings recover. Underlying EBITDA of $67.5m against reported $53.7m signals material add-backs that are not reconciled in the supplied extraction.

Unresolved

• What exactly drives the $19–20m gap between after-tax continuing profit implied by PBT and the $5.2m attributable to equity holders? Non-controlling interests are the most likely explanation but the release does not name the line.
• What is the bridge between underlying EBITDA of $67.5m and reported EBITDA of $53.7m, and which items are treated as non-recurring?
• How much of the revenue and EBITDA decline is Cyclone Gabrielle volume loss versus Global Proteins price and Logistics volume weakness, and does management expect a recovery path in FY24?
• With gross borrowings up 59.7% while cash also rose, what is the funding purpose — working-capital timing, capex pre-funding, or M&A headroom?

This briefing cannot assess forward earnings power, segment profitability, or the specific composition of the NPAT shortfall, because segment EBITDA, a non-GAAP reconciliation, an NCI disclosure, and any FY24 outlook are not present in the supplied extraction.

Key metrics

Segment breakdown

Analytical metrics

---

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.